Group 1: Market Overview - The overall market shows a mixed performance with the Shanghai Composite Index closing at 4128.37, up by 0.13%, while the ChiNext Index fell by 0.37% to 3320.54 [8][9] - The AI application sector is leading the market, particularly with the launch of ByteDance's Seedance 2.0, which enhances video generation capabilities [8][10] - The trading volume decreased, with a total market turnover of 21,247.45 billion, down by 1,454.35 billion from the previous trading day [9] Group 2: Industry Dynamics - ByteDance's Seedance 2.0 has been launched, enabling the creation of high-quality videos from text or images, which is expected to revolutionize the film industry [27][28] - The 2025 Hunan electricity market settlement report indicates a retail settlement average price of 0.45 yuan per kilowatt-hour, with significant transaction volumes reported [29][30] Group 3: Company Updates - Semiconductor company SMIC reported a 23.2% year-on-year increase in net profit for Q4 2025, with total revenue reaching 178.13 billion, a growth of 11.9% [31][32] - Heng Rui Medicine's application for the marketing license of its drug has been accepted and prioritized for review, targeting HER2-positive colorectal cancer [34] - Huami New Materials reported stable growth with a revenue increase of 6.44% and a net profit increase of 10.86% for 2025 [35][36] Group 4: Economic Initiatives - Hunan Province has initiated ten key livelihood projects for 2026, with a total investment of 601 billion, reflecting a 5.2% increase from 2025 [38][39]

Core Viewpoint - The announcement details a change in the equity structure of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. due to the passive reduction of shares held by its controlling shareholder, Heilongjiang Chuangda Group Co., Ltd., following the conversion of exchangeable bonds [2][3]. Group 1: Equity Change Overview - After the equity change, Heilongjiang Chuangda Group holds 516,973,085 shares, representing 54.94% of the total share capital of Zhenbaodao [2][3]. - The equity change is a result of the conversion of exchangeable bonds issued by Chuangda Group, leading to a decrease in its shareholding from 55.86% to 54.94% [3][4]. Group 2: Details of the Equity Change - From February 5 to February 9, 2026, a total of 8,709,675 shares were converted, accounting for approximately 0.93% of the total share capital [4][11]. - The equity change does not trigger a mandatory tender offer and will not alter the controlling shareholder or actual controller of the company [2][5]. Group 3: Future Plans and Compliance - Chuangda Group's exchangeable bonds are currently in the conversion period, and the company will continue to monitor the conversion activities [5][8]. - The company has committed to fulfilling its information disclosure obligations in accordance with relevant laws and regulations [5][8].

Core Viewpoint - The company, Gilead Sciences-B (01672.HK), has selected its first oral glucagon-like peptide-1 receptor agonist, ASC36 oral tablets, for clinical development, with plans to submit an Investigational New Drug (IND) application to the FDA in Q2 2026 for obesity treatment [1][2] Group 1 - ASC36 oral tablets have shown an absolute oral bioavailability of 6% to 8% in non-human primate studies, utilizing Gilead's proprietary oral peptide delivery enhancement technology (POTENT) [1] - In non-human primates, ASC36 oral tablets led to an average weight reduction of up to 13.2% relative to baseline after 7 days of once-daily dosing, significantly reducing food intake [1] - In a head-to-head study using a diet-induced obesity (DIO) rat model, ASC36 demonstrated weight loss effects that were approximately 32% and 91% greater compared to eloralintide and petrelintide, respectively [1] Group 2 - The company has three key glucagon-like peptide-1 candidates: oral small molecule GLP-1, oral GLP-1 peptide, and monthly subcutaneous GLP-1 peptide, with ASC36 oral tablets being a significant GLP-1 agonist [2] - Gilead's competitive and differentiated product pipeline is supported by three proprietary technology platforms: AISBDD, Ultra-Long-Acting Platform (ULAP), and POTENT, aimed at addressing diverse treatment needs for obesity and other metabolic diseases [2]

Core Viewpoint - The company has received a regulatory decision from the Jilin Securities Regulatory Bureau, requiring it to rectify issues related to its governance and independence, particularly concerning its relationship with its controlling shareholder, Dongbao Group [1][2]. Group 1: Regulatory Decision and Company Response - The company has acknowledged the regulatory decision and has communicated it to relevant stakeholders, including its controlling shareholder and management [2]. - A board meeting was held to review and approve a rectification report in response to the regulatory decision [2]. Group 2: Identified Issues and Rectification Measures - The company and its controlling shareholder have been found to have overlapping property usage without formal rental agreements, indicating a lack of independence [3]. - To address this, the company signed a property lease agreement with Dongbao Group, specifying the rental terms for shared properties, ensuring market-based pricing for rent [4][5]. - The company will enhance training for its management and board members on compliance with relevant laws and regulations to improve operational standards [6]. Group 3: Rectification Status and Future Plans - The company has appointed specific individuals and departments responsible for the rectification process, and the measures have been completed [7]. - The company plans to maintain a focus on standardized governance and independence management in the long term [7]. - The regulatory inspection has provided valuable guidance for improving the company's governance level, and the company aims to strengthen its compliance and risk management systems [8].

Core Viewpoint - The company, Gilead Sciences, has announced the selection of its first oral glucagon-like peptide-1 (GLP-1) receptor agonist, ASC36, for clinical development, with plans to submit an Investigational New Drug (IND) application to the FDA by Q2 2026 [1] Group 1: Drug Development and Clinical Trials - ASC36 oral tablets are developed using Gilead's proprietary oral peptide delivery enhancement technology (POTENT) [1] - The absolute oral bioavailability of ASC36 in non-human primates is 8% for the 10 mg dose and 6% for the 25 mg dose, with elimination half-lives of 116 hours and 167 hours respectively, supporting less frequent dosing [1][2] - The drug has shown significant weight loss effects in both non-human primates and diet-induced obesity (DIO) rat models, achieving up to a 13.2% reduction in average body weight relative to baseline after 7 days of treatment [2] Group 2: Comparative Efficacy and Manufacturing Advantages - ASC36 demonstrated approximately 32% and 91% greater weight loss compared to eloralintide and petrelintide, respectively, in head-to-head DIO rat models [2] - The potential for superior oral bioavailability and efficacy may allow for lower dosing compared to recently FDA-approved GLP-1R agonists, which could lead to cost advantages in large-scale production [2] - ASC36 is part of a broader pipeline of insulin candidates, including oral small molecule insulin and monthly subcutaneous insulin peptides, leveraging Gilead's three proprietary technology platforms: AI-assisted structure-based drug discovery (AISBDD), ultra-long-acting drug development platform (ULAP), and POTENT [3]

Overview - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that its subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has had its drug registration application for Benzocaine Gel accepted by the National Medical Products Administration [2] Drug Information and Research Status - The drug is a chemical product independently developed by the group, intended for transdermal local anesthesia, suitable for adults and infants over one month old [3] - As of December 2025, the cumulative R&D investment for this drug is approximately RMB 7.19 million (unaudited) [4] - According to the latest IQVIA CHPA data, the estimated sales for Benzocaine Gel in mainland China (excluding Hong Kong, Macau, and Taiwan) is approximately RMB 443 million in 2024 [4] Impact on the Company - The acceptance of the drug registration application will not have a significant impact on the group's current performance, as commercial production is contingent upon passing GMP compliance checks and obtaining drug registration approval [5] - The specific sales performance of the drug post-launch may be influenced by factors such as medication demand, market competition, and sales channels, which carry a high degree of uncertainty [5]

Group 1 - The company, Shanghai Xuantai Pharmaceutical Technology Co., Ltd., has participated in the national organized procurement for the first to eighth batches of expiring agreements and has been proposed for selection in the continuation procurement for its product, ursodeoxycholic acid capsules [1] - The proposed selection will allow medical institutions to prioritize the use of the selected drug, ensuring the completion of the agreed procurement volume, which is expected to positively impact the company's sales scale, market share, and brand influence [1] Group 2 - The final selection data will be based on the results published by the continuation procurement office [1]

Core Viewpoint - The first prescription of the innovative drug "Sitagliptin Malate Tablets" was issued in Shanghai, marking a significant milestone for Shanghai Pharmaceutical Group and the treatment of primary hypertension [1][3]. Group 1: Drug Overview - "Sitagliptin Malate Tablets" is a first-class innovative drug developed by Shanghai Pharmaceutical Group, representing a new generation of oral non-peptide renin inhibitors [1][6]. - The drug is primarily used for treating primary hypertension, which accounts for over 90% of hypertension cases, as opposed to secondary hypertension caused by identifiable diseases [3][4]. Group 2: Clinical Efficacy - Clinical evidence indicates that the drug can effectively reduce systolic blood pressure by 10-15 mmHg and diastolic blood pressure by 5-10 mmHg, with effects observable from the first day of use [3][4]. - The approval of the drug was based on a rigorously designed Phase III clinical trial led by Professor Ma Changsheng, involving nearly 40 top cardiovascular clinical centers across China [4]. Group 3: Strategic Initiatives - The Pudong New Area has implemented a "3F" strategy (First-in-Class, First-in-China, First-in-Human) to expedite the clinical application of innovative drugs, with the health commission prioritizing the inclusion of this drug in the recommended directory [6]. - The successful launch of this drug reinforces the confidence of Shanghai Pharmaceutical's R&D team in future innovative drug development, supported by ongoing optimization of the biopharmaceutical industry ecosystem in Pudong [6].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Ascletis Pharma Inc. 歌禮製藥有限公司 ASC36口服片由歌禮利用其專有的口服多肽遞送增強技術(POTENT)開發而成。 在非人靈長類動物中，10毫克ASC36口服片在每只動物中每日一次給藥，給藥7 天後，穩態下的絕對口服生物利用度(absolute oral bioavailability)[1]為8%，消除半 衰期(elimination half-life)達116小時；25毫克ASC36口服片在每只動物中每日一 1 － 在非人靈長類動物研究中，通過利用歌禮口服多肽遞送增強技術(POTENT)， ASC36口服片在穩態下的絕對口服生物利用度達6%至8%。 － 在非人靈長類動物中，ASC36口服片每日一次給藥7天後，使相對基線的平 均體重下降高達13.2%。ASC36片亦顯著減少了食物攝入。 － 在一項頭對頭飲食誘導肥胖(DIO)大鼠模型中，與eloralintide和petre ...

Core Insights - The new round of national centralized procurement for medicines has resulted in 4,163 products from 1,020 companies being shortlisted, covering 316 commonly used drugs across 26 therapeutic areas [1][2] - The procurement results are expected to be implemented by the end of March 2026, with the procurement cycle lasting until the end of 2028 [1] - The procurement process has seen a high participation rate from qualified companies, with an overall selection rate of 93%, indicating a diverse market supply and rich clinical choices [1] Group 1 - The centralized procurement is the first nationwide continuation of chemical drug procurement organized by the state, led by the medical insurance bureaus of Jiangsu, Henan, and Guangdong provinces [1] - The procurement rules have been standardized and unified across provinces, significantly reducing bidding costs for companies [1] - The clinical demand matching rate for the reported brand names reached 88%, with a high retention rate of previously selected products at 98%, which helps avoid medication replacement [1] Group 2 - The qualification threshold for bidding has been raised, with stricter quality requirements, including the need for companies to have experience in producing similar types of drugs and no violations of production quality management standards in the past two years [2] - The procurement adopted a pricing inquiry method based on previous winning prices, allowing companies to accurately calculate cost-benefit ratios and rationally quote prices, leading to stable selection prices and industry expectations [2]